Lung Cancer

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Sevabertinib showed high response rates and durable disease control in patients with HER2-mutant NSCLC, with diarrhea as the main manageable side effect.

LiveLung, a nonprofit organization, invites the CSRA’s lung cancer community to its educational meeting.

Brittney Nichols discussed the emotional and physical side effects of lung cancer treatment, as well as feelings of isolation in newly diagnosed patients.

Brittney Nichols highlights the need for early detection and stresses that lung cancer is not only caused by smoking; anyone can develop the disease.

Although a cancer diagnosis can feel overwhelming and isolating, patients should know that they are never alone, Brittney Nichols emphasized.

The FDA granted fast track designation to VT3989 for unresectable malignant nonpleural or pleural mesotherlioma.

LiveLung, a nonprofit organization dedicated to supporting lung cancer patients, invites the Charlotte cancer community to its monthly educational meeting.

Dr. Nicolas Girard discussed the current treatment options for patients with EGFR-mutant lung cancer, including emerging combination regimens.

As we approach Lung Cancer Awareness Month this November, it’s important to reflect on the latest developments and insights in lung cancer research.

Dr. Fred Hirsch highlighted how knowledge of the molecular characteristics of non-small cell lung cancer enhances understanding of the disease.

In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival.

Kelly Dyckman works to help women reclaim their confidence in intimacy following a cancer journey, as she explained in an interview with CURE.

The FDA has approved Zepzelca with Tecentriq or Tecentriq Hybreza for extensive-stage small cell lung cancer.

Lung cancer can be overwhelming, but learning about types, stages, treatments and support can help patients feel more prepared for their care journey.

Prior to my diagnosis with Stage 3B Lung Cancer, I had spent many years reading self-help books. I worked hard, but never felt successful, or took pride in myself.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Adding Tecentriq to chemoradiation improved quality of life and supported twice-daily radiation for patients with limited-stage small cell lung cancer.

Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.

For patients with cancer grappling with nausea or vomiting due to their treatments, a potential side effect remedy may be found in their own hands.

Dr. Edgardo Santos explains that combining Tagrisso with chemotherapy or Leclaza plus Rybrevant may improve survival versus monotherapy alone.